How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Combined Oral Contraceptive Pill Market
- By Generation: First Generation, Second Generation, Third Generation, Fourth Generation
- By Hormonal Composition: Monophasic Pills, Biphasic Pills, Triphasic Pills, Quadriphasic Pills
- By Estrogen Type: Ethinylestradiol-based, Estradiol valerate-based, Estradiol-based
- By Progestin Type: Levonorgestrel, Norgestimate, Drospirenone, Desogestrel, Dienogest
- By Prescription Status: Prescription Only, Over-the-Counter
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - First Generation leads By Generation at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Combined Oral Contraceptive Pill Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Organon & Co.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →HRA Pharma (a Sanofi company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Boehringer Ingelheim
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Cipla Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sun Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Gedeon Richter Plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Hetero Drugs Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Lupin Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Zydus Cadila
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- First Generation52.6
- Second Generation14.2
- Third Generation20.3
- Fourth Generation13.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Bayer AG16.2
- Pfizer Inc.22.0
- Teva Pharmaceutical Industries Ltd.7.9
- Mylan N.V. (now part of Viatris)7.4
- Organon & Co.7.9
- HRA Pharma (a Sanofi company)10.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.2
- Europe23.1
- Asia Pacific21.1
- Latin America11.0
- Middle East and Africa9.7
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Bayer AG | 93 | 89 | 88 | 92 | 87 | 79 | 88 |
| Pfizer Inc. | 69 | 93 | 77 | 78 | 68 | 93 | 80 |
| Teva Pharmaceutical Industries Ltd. | 83 | 62 | 83 | 79 | 76 | 71 | 76 |
| Mylan N.V. (now part of Viatris) | 79 | 77 | 60 | 76 | 77 | 71 | 73 |
| Organon & Co. | 70 | 76 | 71 | 67 | 56 | 71 | 69 |
| HRA Pharma (a Sanofi company) | 64 | 64 | 56 | 60 | 61 | 55 | 60 |
| Boehringer Ingelheim | 53 | 47 | 53 | 52 | 48 | 59 | 52 |
| Cipla Limited | 52 | 52 | 46 | 41 | 51 | 42 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Bayer AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Bayer AG | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Pfizer Inc. | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ✓ | − | ✓ | ✓ | ✓ | ✓ |
| Mylan N.V. (now part of Viatris) | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Organon & Co. | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| HRA Pharma (a Sanofi company) | ◐ | ◐ | − | − | − | ◐ |
| Boehringer Ingelheim | − | − | − | − | ◐ | ◐ |
| Cipla Limited | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger3
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Generation in North America, then scale across Combined Oral Contraceptive Pill Market — a $534M beachhead inside a $8.32B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →First Generation
Best fit — highest urgency & budget in Generation.
Second Generation
Strong fit — clear ROI and a fast path to value.
Third Generation
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Generation in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Hormonal Composition & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Estrogen Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Generation leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Combined Oral Contraceptive Pill Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Combined Oral Contraceptive Pill Market is a high-growth opportunity — $1.44B by 2033, compounding at 10.4%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Generation.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Generation moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Hormonal Composition optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Combined Oral Contraceptive Pill Market — a $1.68B market by 2033. Plan: grow share from 7.6% to 14.4%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 14.4% | At risk |
| Revenue | $134M | $242M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.3% | 38.2% | On track |
| Customer retention | 88.0% | 93.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Generation
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Hormonal Composition capability
A defensible second engine — invest in Hormonal Composition to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Generation share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Hormonal Composition
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $26M capacity & capability investment
- Greenlight bolt-on M&A in Hormonal Composition
- Authorise North America expansion plan
- Fund R&D program for Generation leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Sales deck · value proposition
Win the Combined Oral Contraceptive Pill Market conversation — a $945M market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Generation
Goal Grow share in Generation
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Combined Oral Contraceptive Pill Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Combined Oral Contraceptive Pill Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Combined Cotton-Filled Dressings Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportCombination Vital Signs Monitors Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportCombination Treatment in Aesthetic Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCombination Therapies In Aesthetics Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportCombination Stretchers Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCombination Scales Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportCombination Preventers Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportCombination Inhaler Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportDigital Nose technology Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCombination Eyewash Showers Market
Market size, share, segmentation and regional forecast.
$697M market · 2025 base year
View reportCombination Anti-Diabetes Drugs Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportComa Treatment Devices Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy